Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Mar 26;6(1):69-71.
doi: 10.1515/dx-2018-0098.

Diagnostic error as a result of drug-laboratory test interactions

Affiliations
Free article
Review

Diagnostic error as a result of drug-laboratory test interactions

Jasmijn A van Balveren et al. Diagnosis (Berl). .
Free article

Abstract

Background Knowledge of possible drug-laboratory test interactions (DLTIs) is important for the interpretation of laboratory test results. Test results may be affected by physiological or analytical drug effects. Failure to recognize these interactions may lead to misinterpretation of test results, a delayed or erroneous diagnosis or unnecessary extra tests or therapy, which may harm patients. Content Thousands of interactions have been reported in the literature, but are often fragmentarily described and some papers even reported contradictory findings. How can healthcare professionals become aware of all these possible interactions in their individual patients? DLTI decision support applications could be a good solution. In a literature search, only four relevant studies have been found on DLTI decision support applications in clinical practice. These studies show a potential benefit of automated DLTI messages to physicians for the interpretation of laboratory test results. All physicians reported that part of the DLTI messages were useful. In one study, 74% of physicians even sometimes refrained from further additional examination. Summary and outlook Unrecognized DLTIs potentially cause diagnostic errors in a large number of patients. Therefore, efforts to avoid these errors, for example with a DLTI decision support application, could tremendously improve patient outcome.

Keywords: (computerized) clinical decision support; clinical laboratory test; diagnostic error; drug-laboratory test interaction; patient safety.

PubMed Disclaimer

Similar articles

  • Drug interference with biochemical laboratory tests.
    Katanić J, Stanimirov B, Sekeruš V, Đanić M, Pavlović N, Mikov M, Stankov K. Katanić J, et al. Biochem Med (Zagreb). 2023 Jun 15;33(2):020601. doi: 10.11613/BM.2023.020601. Epub 2023 Apr 15. Biochem Med (Zagreb). 2023. PMID: 37143715 Free PMC article. Review.
  • Impact of interactions between drugs and laboratory test results on diagnostic test interpretation - a systematic review.
    van Balveren JA, Verboeket-van de Venne WPHG, Erdem-Eraslan L, de Graaf AJ, Loot AE, Musson REA, Oosterhuis WP, Schuijt MP, van der Sijs H, Verheul RJ, de Wolf HK, Kusters R, Hoedemakers RMJ; Dutch Society for Clinical Chemistry and Laboratory Medicine, task group ‘SMILE’: Signaling Medication Interactions and Laboratory test Expert system. van Balveren JA, et al. Clin Chem Lab Med. 2018 Nov 27;56(12):2004-2009. doi: 10.1515/cclm-2018-0900. Clin Chem Lab Med. 2018. PMID: 30332390
  • Clinical usefulness of drug-laboratory test interaction alerts: a multicentre survey.
    van Balveren JA, Verboeket-van de Venne WPHG, Doggen CJM, Cornelissen AS, Erdem-Eraslan L, de Graaf AJ, Krabbe JG, Musson REA, Oosterhuis WP, de Rijke YB, van der Sijs H, Tintu AN, Verheul RJ, Hoedemakers RMJ, Kusters R; Dutch Society for Clinical Chemistry and Laboratory Medicine; task group ‘SMILE’: Signaling Medication Interactions and Laboratory test Expert system. van Balveren JA, et al. Clin Chem Lab Med. 2021 Feb 25;59(7):1239-1245. doi: 10.1515/cclm-2020-1770. Print 2021 Jun 25. Clin Chem Lab Med. 2021. PMID: 33645171
  • Real-time monitoring of drug laboratory test interactions: a proof of concept.
    van Balveren JA, Verboeket-van de Venne WPHG, Doggen CJM, Erdem-Eraslan L, de Graaf AJ, Krabbe JG, Musson REA, Oosterhuis WP, de Rijke YB, van der Sijs H, Tintu AN, Verheul RJ, Hoedemakers RMJ, Kusters R. van Balveren JA, et al. Clin Chem Lab Med. 2021 Nov 9;60(2):235-242. doi: 10.1515/cclm-2021-0790. Print 2022 Jan 27. Clin Chem Lab Med. 2021. PMID: 34751523
  • FDA-approved drugs that interfere with laboratory tests: A systematic search of US drug labels.
    Yao H, Rayburn ER, Shi Q, Gao L, Hu W, Li H. Yao H, et al. Crit Rev Clin Lab Sci. 2017 Jan;54(1):1-17. doi: 10.1080/10408363.2016.1191425. Epub 2016 Jun 27. Crit Rev Clin Lab Sci. 2017. PMID: 27193822 Review.

Cited by

References

    1. Whiting PF, Davenport C, Jameson C, Burke M, Sterne JA, HydeC, et al. How well do health professionals interpret diagnostic information? A systematic review. BMJ Open 2015;5:1–8.
    1. Vlasveld LT, van ’t Wout J, Castel A. False elevation of chromogranin A due to proton pump inhibitors. Neth J Med 2011;69:207.
    1. Perera NJ, Stewart PM, Williams PF, Chua EL, Yue DK, Twigg SM. The danger of using inappropriate point-of-care glucose meters in patients on icodextrin dialysis. Diabet Med 2011;28:1272–6.
    1. FDA. Public health notification: potentially fatal errors with GDH-PQQ glucose monitoring technology, 2009. Available at: http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/PublicHealthNo....
    1. Young DS. Effects of drugs on clinical laboratory tests, 5th ed. Washington: American Association of Clinical Chemistry, 2000.

Publication types

LinkOut - more resources